Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer

Sun, Lin; Zhou, Hongbin; Yang, Ying; Chen, Jianguo; Wang, Yong; She, Min; Li, Chang

doi:10.1042/bsr20200349

Cited by 17 publications

(19 citation statements)

References 32 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…despite improvements in preventative and therapeutic strategies in recent decades, the 5-year survival rate is still low of only 15-20% (1). non-small cell lung cancer (nSclc) accounts for 85% of lung cancer cases (2). The survival of patients with NSCLC has significantly improved following the development of chemotherapy and molecular targeted therapy.…”

Section: Introductionmentioning

confidence: 99%

Effect of AGER on the biological behavior of non‑small cell lung cancer H1299 cells

et al. 2020

View full text Add to dashboard Cite

advanced glycosylation end-product specific receptor (aGer) is a multi-ligand cell surface receptor abnormally expressed in lung cancer, and is a member of the immunoglobulin superfamily. Therefore, this study aimed to explore the effect of aGer on the biological behavior of non-small cell lung cancer (nSclc) H1299 cell line. a microarray-based gene expression profiling analysis of the GSe27262 dataset from the Gene expression omnibus (Geo) database was conducted to identify differentially expressed genes, which were verified using The Cancer Genome Atlas (TcGa) database. The expression of aGer in the normal human lung BeaS-2B cell line and nSclc H1299 cell line was examined using reverse transcription-quantitative Pcr. lentiviral interference and overexpression vectors of aGer were constructed and transfected into H1299 cells using lipofectamine ® . aGer expression and biological properties, including cell viability, apoptosis, migration and invasion abilities, in H1299 cells were investigated using MTT, flow cytometry, wound healing and Transwell assays. aGer was expressed at a low level in nSclc tissues and H1299 cells (P<0.05). compared with control cells, aGer overexpression cells displayed decreased cell viability, proliferation, migration and invasion abilities, and significantly increased levels of apoptosis. Furthermore, aGer overexpression increased the expression of Bax and decreased the expression of Bcl-2 in H1299 cells (P<0.05), and aGer knockdown displayed the opposite effects on H1299 cells. Therefore, aGer overexpression decreased the proliferation, invasion and migration abilities of H1299 cells, and increased apoptosis. The present study suggested that aGer might serve as a potential molecular marker for nSclc.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of AGER on the biological behavior of non‑small cell lung cancer H1299 cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Downregulation of serum miR-770 was significantly associated with shorter survival and aggressive clinical parameters. 10 MiR-185 have been previously identified as a tumor suppressive miRNA in NSCLC. [11][12][13][14] However, currently little information is available for the potential clinical value of serum miR-185 in NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Serum miR-185 Is a Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer

Liu

Han

Liu

et al. 2020

Technol Cancer Res Treat

View full text Add to dashboard Cite

Objective: MicroRNAs (miRNAs) have been found to play important roles in the development of non-small cell lung carcinoma (NSCLC). The aim of this study was to analyze the expression and clinical value of serum miR-185 in NSCLC. Methods: Serum miR-185 levels were detected in 146 NSCLC patients, 50 patients with carcinoma in situ, 25 patients with non-malignant lung diseases (NMLD), and 80 healthy controls using quantitative reverse transcription PCR. The correlation between serum miR-185 level and clinical status of NSCLC was explored. Results: The results revealed that serum miR-185 expression was progressively decreased in healthy controls, patients with NMLD, patients with carcinoma in situ and NSCLC patients. In addition, compared to carcinoembryonic antigen (CEA), serum miR-185 demonstrated better diagnostic accuracy for discriminating patients with carcinoma from healthy controls, NSCLC patients from healthy controls and NSCLC patients from patients with carcinoma in situ. In addition, serum miR-185 levels were significantly elevated in post-treated samples compared to the pre-treated samples. Moreover, reduced serum miR-185 was closely associated with unfavorable clinicopathological parameters and worse survival. Univariate and multivariate cox regression analysis confirmed that serum miR-185 was an independent prognostic indicator for NSCLC. Conclusions: Collectively, our findings have demonstrated that serum miR-185 might serve as a promising and robust biomarker for the early detection and prognosis prediction of NSCLC.

show abstract

“…The expression of miR-126 is found to be reduced in colorectal, prostate, bladder and gastric cancer [10]. Similar phenomenon was found in lung cancer cell lines [11]. Thus, miR-126 may highly involve in pathogenesis of lung cancer.…”

Section: Introductionmentioning

confidence: 59%

Knockdown of microRNA-126 Suppresses Non-Small-Cell Lung Cancer via Inhibiting PI3K-AKT-mTOR Pathway

Chen

Ping

et al. 2021

Preprint

View full text Add to dashboard Cite

Background As one of the most common cause of cancer death in the world, lung cancer causes approximate 1.6 million deaths annually. Among, NSCLC accounts approximately 85% of patients in whole lung cancer patients. As one of miRNAs, miR-126 closely involves in pathogenesis of several types of cancers including colorectal, prostate, bladder and gastric cancer, and so on. Thus, the present study aims to investigate effects of miR126 on pathogenesis of NSCLC. In the study, two lung cancer cell lines including A549 and H1650 were used. Results It was found that expression of miR126 was decreased in PBMC of NSCLC patients compared to healthy control. Expression of miR126 was decreased in cancer tissue compared to paracancerous tissues in NSCLC patients. MiR-126 KD remarkably increased expression of apoptosis genes including caspase3 and capsae9, and decreased cell viability in lung cancer cells including A549 and H1650 cells. Interesting, In Silico analysis indicated that miR-126 could target PI3K signaling pathway, which was confirmed by WB assay. KD of PI3KR2 compromised promotion of miR-126 on cell apoptosis. Similarly, it was found that KD of mTOR compromised promotion of miR-126 on cell apoptosis. Conclusions Thus, the present study confirmed that miR-126 plays an important role in apoptosis of lung cells via mTOR signaling pathway. miR-126 might be a potential therapeutic target for developing novel drugs against NSCLC.

show abstract

Meta-analysis of diagnostic and prognostic value of miR-126 in non-small cell lung cancer

Cited by 17 publications

References 32 publications

Effect of AGER on the biological behavior of non‑small cell lung cancer H1299 cells

Effect of AGER on the biological behavior of non‑small cell lung cancer H1299 cells

Serum miR-185 Is a Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer

Knockdown of microRNA-126 Suppresses Non-Small-Cell Lung Cancer via Inhibiting PI3K-AKT-mTOR Pathway

Contact Info

Product

Resources

About